ABCB1
Overview
ABCB1 (also known as MDR1 or P-glycoprotein) encodes an ATP-binding cassette transporter that functions as an energy-dependent efflux pump. In cancer, ABCB1 overexpression mediates multidrug resistance by reducing intracellular accumulation of chemotherapy agents including anthracyclines, taxanes, vinca alkaloids, and epipodophyllotoxins. Its expression is studied extensively in the NCI-60 cell line panel as a pharmacogenomic marker correlating drug activity patterns with resistance phenotypes.
Alterations observed in the corpus
- Overexpression of ABCB1 in NCI-60 cell lines is associated with multidrug resistance; P-glycoprotein efflux reduces intracellular concentrations of doxorubicin and romidepsin, identified through CellMiner pharmacogenomic pattern comparison PMID:22802077
Cancer types (linked)
- Colon cancer (COAD): ABCB1 overexpression patterns analyzed in NCI-60 colon cancer cell lines via CellMiner; drug-activity correlations used to predict resistance profiles PMID:22802077
Co-occurrence and mutual exclusivity
- No co-occurrence or mutual exclusivity data in the current corpus.
Therapeutic relevance
- ABCB1 expression predicts resistance to doxorubicin and romidepsin in NCI-60 cell lines; pattern-matching via CellMiner can flag ABCB1-driven efflux as a potential resistance mechanism prior to drug selection PMID:22802077
Open questions
- Whether ABCB1 expression levels in NCI-60 cell lines translate to clinical resistance in patient tumors remains unresolved; the NCI-60 panel lacks in vivo microenvironment and immune interactions PMID:22802077
Sources
This page was processed by entity-page-writer on 2026-05-06.